GAAP results for the three and six month periods ended June 30, 2008 and June 30, 2007 include certain non-cash debt financing expenses related to the Company's convertible notes and convertible mandatorily redeemable preferred stock. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information, which are adjusted net income and adjusted earnings per share, excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results appears below. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang
Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd.
("En ze"), two Chinese pharmaceutical companies located in Beijing
(together "Lotus East"). Lotus East is a comprehensive enterprise, which
deals in an integration of the production, trade, sales and marketing of
pharmaceuticals. The Company possesses some of the most advanced
pharmaceutical-production equipment used in China, workshops authenticated
by the National GMP, a suite of various medicines produced by Lotus East,
and a number of high-tech personnel. Lotus East has business and office
facilities of 2,000 square meters, warehouse of 1,000 square meters and
operates ten retail pharmacies in the Beijing area. Lotus East performs
scientific research on new medicines, and the production, wholesale and
retail sale of medicines through 10 retail pharmacy locations through
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved